C
EGRX

Covestor’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Covestor’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-116
Closed -$1K – 2863
2023
Q4 		$1K Buy
116
+31
+36% +$306 ﹤0.01% 2063
2023
Q3 		$1K Buy
85
+23
+37% +$413 ﹤0.01% 2031
2023
Q2 		$1K Buy
62
+18
+41% +$427 ﹤0.01% 2046
2023
Q1 		$1K Sell
44
-21
-32% -$623 ﹤0.01% 1922
2022
Q4 		$2K Buy
65
+46
+242% +$1.46K ﹤0.01% 1821
2022
Q3 		$1K Buy
+19
New +$697 ﹤0.01% 1887
2022
Q2 		– Sell
-111
Closed -$6K – 2460
2022
Q1 		$6K Buy
111
+66
+147% +$3.17K ﹤0.01% 1473
2021
Q4 		$2K Buy
+45
New +$2.33K ﹤0.01% 1595

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Covestor's EGRX Position: Q1 2024 in Review

Covestor sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 116 shares — an estimated $1K sold.

Covestor first reported a position in EGRX in Q4 2021 and held it in 8 quarters. The position peaked at $6K in Q1 2022. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

  • Covestor reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Covestor sold 116 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $1K.
  • Covestor first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2021 and held it in 8 quarters.
  • Covestor's Eagle Pharmaceuticals, Inc. position peaked at $6K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Covestor's 13F filing for Q1 2024, filed 10 May 2024.